- Record: found
- Abstract: found
- Article: not found
Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Paul Lorigan
1 ,
Jaap Verweij ,
Zsuzsa Papai ,
Sjoerd Rodenhuis ,
Axel Le Cesne ,
Michael G Leahy ,
John A Radford ,
Martine M Van Glabbeke ,
Anne Kirkpatrick ,
Pancras C W Hogendoorn ,
Jean-Yves Blay
Jul 20 2007
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Single-agent doxorubicin remains the standard treatment for advanced soft tissue sarcomas. Combining doxorubicin with standard-dose ifosfamide has not been shown to improve survival and is associated with a significantly increased toxicity; it is not known whether higher dose single-agent ifosfamide is superior to doxorubicin.